Phase I study of pazopanib and ixabepilone in patients with solid tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 3, 2016, Pages 280-287

  Ganesan, Chitra ^a   Obulareddy, Sri J ^b   Fischer, James H ^c   Antonysamy, Mary A ^a   Jha, Gautam ^a   Bliss, Robin L ^a   Dudek, Arkadiusz Z ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Advanced solid tumor; Ixabepilone; Pazopanib; Safety; SE selectin

Indexed keywords

CYTOKINE; IXABEPILONE; PAZOPANIB; SELECTIN; ANTINEOPLASTIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPOTHILONE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ATRIAL FIBRILLATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MINIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOPLASMS; PATHOLOGY; RETREATMENT; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CYTOKINES; DISEASE-FREE SURVIVAL; E-SELECTIN; EPOTHILONES; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PYRIMIDINES; RETREATMENT; SULFONAMIDES; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84894372877     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000053     Document Type: Conference Paper

References (24)

1. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429-1437.
2. Jordan MA, Miller H, Ray A, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin, has altered-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res. 2006;47:LB-280a.
3. Lee FYF, Covello KL, Castaneda S, et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Caner Res. 2008;14:8123-8131.
4. Lee FYF, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009;63:201-212.
5. Isham CR, Bossou AR, Negron V, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013;5:166ra3.
6. Aghajanian C, Burris HA III, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007;25:1082-1088.
7. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003;21:1866-1873.
8. Zhuang SH, Agrawal M, Edgerly M, et al. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer. 2005;103:1932-1938.
9. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414.
10. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007; 25:3399-3406.
11. Sternberg CN, David ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
12. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043). J Clin Oncol. 2009;27:3126-3132.
13. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15: 4220-4227.
14. Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a highfat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88:818-823.
15. Thomas Y, Chen P-J, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011;17:6914-6923.
16. Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50:551-603.
17. Wang JY, Zheng YZ, Yang J, et al. Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer. 2012;12:365.
18. Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis. 2008;25:335-344.
19. Tremblay PL, Huot J, Auger FA. Mechanisms by which Eselectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res. 2008;68:5167-5176.
20. Khatib AM, Auguste P, Fallavollita L, et al. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol. 2005;167:749-759.
21. Auguste P, Fallavollita L, Wang N, et al. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol. 2007;170:1781-1792.
22. Sato H, Usuda N, Kuroda M, et al. Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer. Cancer Biomark. 2008;4:43-54.
23. Feronni N, Roselli M, Spila A, et al. Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer. 2010;116:2913-2921.
24. Guney N, Soydinc HO, Derin D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage nonsmall cell lung cancer. Med Oncol. 2008;25:194-200.